News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Gilead Sciences, Inc. (GILD)'s $84,000 Treatment Questioned By U.S. Lawmakers


3/24/2014 6:56:08 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

Gilead Sciences Inc. (GILD) is being asked by U.S. House Democrats to explain how the company set its $84,000 price for hepatitis C treatment Sovaldi. The lawmakers also asked Gilead Chief Executive Officer John Martin to explain what is being done to make sure the medicine gets into the hands of low-income patients, especially in government-run health programs. “Our concern is that a treatment will not cure patients if they cannot afford it,” Democratic representatives Henry Waxman of California, Frank Pallone Jr. of New Jersey, and Diana DeGette of Colorado, wrote in a letter sent yesterday.

Help employers find you! Check out all the jobs and post your resume.

Read at Bloomberg
Read at News Release
Read at News Release
Read at Los Angeles Times


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES